Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) Director Jason Aryeh sold 388,685 shares of Aralez Pharmaceuticals stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $1.44, for a total value of $559,706.40. Following the sale, the director now directly owns 15,000 shares in the company, valued at approximately $21,600. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) remained flat at $1.42 during trading on Wednesday. The company’s stock had a trading volume of 41,739 shares. The stock’s 50-day moving average price is $1.56 and its 200 day moving average price is $3.47. Aralez Pharmaceuticals Inc has a 1-year low of $1.14 and a 1-year high of $6.80. The stock’s market cap is $93.50 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by $0.02. The company had revenue of $26 million during the quarter, compared to analyst estimates of $20.23 million. Aralez Pharmaceuticals had a negative net margin of 211.76% and a negative return on equity of 65.67%. The business’s revenue for the quarter was up 221.0% compared to the same quarter last year. During the same period last year, the company earned ($0.73) EPS. On average, equities analysts anticipate that Aralez Pharmaceuticals Inc will post ($1.56) earnings per share for the current year.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

TRADEMARK VIOLATION WARNING: “Jason Aryeh Sells 388,685 Shares of Aralez Pharmaceuticals Inc (ARLZ) Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/24/jason-aryeh-sells-388685-shares-of-aralez-pharmaceuticals-inc-arlz-stock.html.

ARLZ has been the topic of a number of recent research reports. Bloom Burton upgraded Aralez Pharmaceuticals from an “accumulate” rating to a “buy” rating in a report on Monday, April 10th. Chardan Capital decreased their target price on Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, March 15th.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd bought a new position in Aralez Pharmaceuticals during the fourth quarter worth $103,000. FNY Managed Accounts LLC increased its position in Aralez Pharmaceuticals by 4.2% in the first quarter. FNY Managed Accounts LLC now owns 77,119 shares of the company’s stock worth $165,000 after buying an additional 3,136 shares during the period. J. Goldman & Co LP bought a new position in Aralez Pharmaceuticals during the fourth quarter worth $198,000. Goldman Sachs Group Inc. increased its position in Aralez Pharmaceuticals by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock worth $260,000 after buying an additional 354 shares during the period. Finally, KCG Holdings Inc. bought a new position in Aralez Pharmaceuticals during the first quarter worth $310,000. 44.01% of the stock is currently owned by institutional investors.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

12 Month Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.